Effective Tumor Immunotherapy: Start the Engine, Release the Brakes, Step on the Gas Pedal, ... and Get Ready to Face Autoimmunity

Archivum Immunologiae et Therapiae Experimentalis

Volumn 50, Issue 1, 2002, Pages 13-18

  Tirapu, Iñigo ^a   Mazzolini, Guillermo ^a   Rodriguez Calvillo, Mercedes ^a   Arina, Ainhoa ^a   Palencia, Belen ^a   Gabari, Izaskun ^a   Melero, Ignacio ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

4 1BB; CD40; Costimulation; CTLA 4; Cytokines; Dendritic cells; Immunotherapy

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; INTERLEUKIN 2 RECEPTOR; LEUKOCYTE ANTIGEN;

ANIMAL; AUTOIMMUNITY; DENDRITIC CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, DIFFERENTIATION; AUTOIMMUNITY; DENDRITIC CELLS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0036372821     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. BANCHEREAU J. and STEINMAN R. M. (1998): Dendritic cells and the control of immunity. Nature, 392, 245-252.
2. BASKAR S., OSTRAND-ROSENBERG S., NABAVI N., NADLER L. M., FREEMAN G. J. and GLIMCHER L. H. (1993): Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA, 90, 5687-5690.
3. BIRMINGHAM K. (2001): Misconduct trouble brewing in Gottingen. Nat. Med., 7, 875.
4. BOON T., COULIE P. G. and VAN DEN EYNDE B. (1997): Tumor antigens recognized by T cells. Immunol. Today, 18, 267-268.
5. BOON T. and OLD L. J. (1997): Cancer tumor antigens. Curr. Opin. Immunol., 9, 681-683.
6. BULFONE-PAUS S., UNGUREANU D., POHL T., LINDNER G., PAUS R., RUCKERT R., KRAUSE H. and KUNZENDORF U. (1997): Interleukin-15 protects from lethal apoptosis in vivo. Nat. Med., 3, 1124-1128.
7. + T cell responses. Proc. Natl. Acad. Sci. USA, 96, 8603-8608.
8. CHAMBERS C. A., KUHNS M. S., EGEN J. G. and ALLISON J. P. (2001): CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol., 19, 565-594.
9. CHEN L. (1998): Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today, 19, 27-30.
10. CHEN L., ASHE S., BRADY W. A., HELLSTROM I., HELLSTROM K. E., LEDBETTER J. A., MCGOWAN P. and LINSLEY P. S. (1992): Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71, 1093-1102.
11. + T cells with regulatory properties from human blood. J. Exp. Med., 193, 1303-1310.
12. DRANOFF G., JAFFEE E., LAZENBY A., GOLUMBEK P., LEVITSKY H., BROSE K., JACKSON V., HAMADA H., PARDOLL D. and MULLIGAN R. C. (1993): Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90, 3539-3543.
13. FONG L. and ENGLEMAN E. G. (2000): Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol., 18, 245-273.
14. FONG L., HOU Y., RIVAS A., BENIKE C., YUEN A., FISHER G. A., DAVIS M. M. and ENGLEMAN E. G. (2001): Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA, 98, 8809-8814.
15. FREEMAN G. J., LONG A. J., IWAI Y., BOURQUE K., CHERNOVA T., NISHIMURA H., FITZ L. J., MALENKOVICH N., OKAZAKI T., BYRNE M. C., HORTON H. F., FOUSER L., CARTER L., LING V., BOWMAN M. R., CARRENO B. M., COLLINS M., WOOD C. R. and HONJO T. (2000): Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 192, 1027-1034.
16. FRENCH R. R., CHAN H. T., TUTT A. L. and GLENNIE M. J. (1999): CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med., 5, 548-553.
17. GONG J., CHEN D., KASHIWABA M. and KUFE D. (1997): Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med., 3, 558-561.
18. GONG J., CHEN D., KASHIWABA M., LI Y., CHEN L., TAKEUCHI H., QU H., ROWSE G. J., GENDLER S. J. and KUFE D. (1998): Reversal of tolerance to human MUCI antigen in MUCI transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA, 95, 6279-6283.
19. GUINN B. A., DEBENEDETTE M. A., WATTS T. H. and BERINSTEIN N. L. (1999): 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol., 162, 5003-5010.
20. + T cell adoptive immunotherapy. Immunity, 13, 265-276.
21. HEATH W. R. and CARBONE F. R. (2001): Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol., 19, 47-64.
22. HUANG A. Y., GOLUMBEK P., AHMADZADEH M., JAFFEE E., PARDOLL D. and LEVITSKY H. (1994): Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264, 961-965.
23. INABA K., INABA M., ROMANI N., AYA H., DEGUCHI M., IKEHARA S., MURAMATSU S. and STEINMAN R. M. (1992): Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176, 1693-1702.
24. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med., 193, 1285-1294.
25. KIKUCHI T., MOORE M. A. and CRYSTAL R. G. (2000): Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood, 96, 91-99.
26. KIM J. A., AVERBOOK B. J., CHAMBERS K., ROTHCHILD K., KJAERGAARD J., PAPAY R. and SHU S. (2001): Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res., 61, 2031-2037.
27. KUGLER A., STUHLER G., WALDEN P., ZOLLER G., ZOBYWALSKI A., BROSSART P., TREFZER U., ULLRICH S., MULLER C. A., BECKER V., GROSS A. J., HEMMERLEIN B., KANZ L., MULLER G. A. and RINGERT R. H. (2000): Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 6, 332-336.
28. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med., 193, 1295-1302.
29. LI X. C., DEMIRCI G., FERRARI-LACRAZ S., GROVES C., COYLE A., MALEK T. R. and STROM T. B. (2001): IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med., 7, 114-118.
30. LUDEWIG B., OCHSENBEIN A. F., ODERMATT B., PAULIN D., HENGARTNER H. and ZINKERNAGEL R. M. (2000): Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med., 191, 795-804.
31. LUDEWIG B., OEHEN S., BARCHIESI F., SCHWENDENER R. A., HENGARTNER H. and ZINKERNAGEL R. M. (1999): Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J. Immunol., 163, 1839-1844.
32. LYNCH D. H., ANDREASEN A., MARASKOVSKY E., WHITMORE J., MILLER R. E. and SCHUH J. C. (1997): Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med., 3, 625-631.
33. MARASKOVSKY E., BRASEL K., TEEPE M., ROUX E. R., LYMAN S. D., SHORTMAN K., and MCKENNA H. J. (1996): Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med., 184, 1953-1962.
34. MAZZOLINI G., NARVAIZA I., BUSTOS M., DUARTE M., TIRAPU I., BILBAO R., QIAN C., PRIETO J. and MELERO I. (2001): Alpha(v) beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment. Mol. Ther., 3, 665-672.
35. MAZZOLINI G., QIAN C., NARVAIZA I., BARAJAS M., BORRAS-CUESTA F., XIE X., DUARTE M., MELERO I. and PRIETO J. (2000): Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum. Gene Ther., 11, 113-125.
36. MELERO I., BACH N., HELLSTROM K. E., ARUFFO A., MITTLER R. S. and CHEN L. (1998): Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol., 28, 1116-1121.
37. MELERO I., DUARTE M., RUIZ J., SANGRO B., GALOFRE J., MAZZOLINI G., BUSTOS M., QIAN C. and PRIETO J. (1999): Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther., 6, 1779-1784.
38. MELERO I., MAZZOLINI G., NARVAIZA I., QIAN C., CHEN L. and PRIETO J. (2001): IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol., 22, 113-115.
39. MELERO I., SHUFORD W. W., NEWBY S. A., ARUFFO A., LEDBETTER J. A., HELLSTROM K. E., MITTLER R. S. and CHEN L. (1997): Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med., 3, 682-685.
40. MELERO I., VILE R. G. and COLOMBO M. P. (2000): Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther., 7, 1167-1170.
41. MELIEF C. J., TOES R. E., MEDEMA J. P., VAN DER BURG S. H., OSSENDORP F. and OFFRINGA R. (2000): Strategies for immunotherapy of cancer. Adv. Immunol., 75, 235-282.
42. NARVAIZA I., MAZZOLINI G., BARAJAS M., DUARTE M., ZARATIEGUI M., QIAN C., MELERO I. and PRIETO J. (2000): Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol., 164, 3112-3122.
43. NESTLE F. O., BANCHEREAU J. and HART D. (2001): Dendritic cells: on the move from bench to bedside. Nat. Med., 7, 761-765.
44. NISHIMURA H., NOSE M., HIAI H., MINATO N. and HONJO T. (1999): Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11, 141-151.
45. NISHIOKA Y., HIRAO M., ROBBINS P. D., LOTZE M. T. and TAHARA H. (1999): Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res., 59, 4035-4041.
46. OCHSENBEIN A. F., KLENERMAN P., KARRER U., LUDEWIG B., PERICIN M., HENGARTNER H. and ZINKERNAGEL R. M. (1999): Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA, 96, 2233-2238.
47. OSTRAND-ROSENBERG S., RUBY C. A. and CLEMENTS V. K. (1991): Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol., 147, 2419-2422.
48. + immunoregulatory cells. J. Immunol., 167, 1137-1140.
49. PRZEPIORKA D. and SRIVASTAVA P. K. (1998): Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol. Med. Today, 4, 478-484.
50. SALLUSTO F. and LANZAVECCHIA A. (1994): Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179, 1109-1118.
51. SCHOENBERGER S. P., TOES R. E., VAN DER VOORT E. I., OFFRINGA R. and MELIEF C. J. (1998): T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483.
52. SHIMIZU Y., GUIDOTTI L. G., FOWLER P. and CHISARI F. V. (1998): Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol., 161, 4520-4529.
53. SHURIN M. R., ESCHE C., PERON J. M. and LOTZE M. T. (1997): Antitumor activities of IL-12 and mechanisms of action. Chem. Immunol., 68, 153-174.
54. SUN Y., PENG D., LECANDA J., SCHMITZ V., BARAJAS M., QIAN C. and PRIETO J. (2000): In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther., 7, 1467-1476.
55. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med., 193, 1311-1318.
56. TIMMERMAN J. M. and LEVY R. (1999): Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med., 50, 507-529.
57. TIRAPU I., DUARTE M., RODRÍGUEZ-CALVILLO M., INOGÉS S., LASARTE J. J., SAROSE P., MAZZOLINI G. and MELERO I. (2000): Ignorancia inmunológica de antígenos tumorales e inyección intratumoral de células del sistema inmunitario. Inmunología, 19, 134-138.
58. TODRYK S. M., TUTT A. L., GREEN M. H., SMALLWOOD J. A., HALANEK N., DALGLEISH A. G. and GLENNIE M. J. (2001): CD40 ligation for immunotherapy of solid tumours. J. Immunol. Methods, 248, 139-147.
59. VAN ELSAS A., HURWITZ A. A. and ALLISON J. P. (1999): Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med., 190, 355-366.
60. VAN ELSAS A., SUTMULLER R. P., HURWITZ A. A., ZISKIN J., VILLASENOR J., MEDEMA J. P., OVERWUK W. W., RESTIFO N. P., MELIEF C. J., OFFRINGA R. and ALLISON J. P. (2001): Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine. Comparison of prophylaxis and therapy. J. Exp. Med., 194, 481-490.
61. YEE C., RIDDELL S. R. and GREENBERG P. D. (1997): Prospects for adoptive T cell therapy. Curr. Opin. Immunol., 9, 702-708.
62. + T cells in vivo by IL-15. Immunity, 8, 591-599.